Founded in 2019, Zenitar is an innovative drug R&D company driven by structural biology and artificial intelligence. Zenitar focuses on key therapeutic areas such as oncology, autoimmune diseases, inflammation, and neurological disorders, dedicated to discovering, developing, and commercializing First-in-class and Best-in-class innovative drugs.

Zenitar has independently developed 7 global products with differentiation and international competitiveness, building a pipeline covering multiple major disease areas. Among them, its core product Purinostat Mesylate (PM), the world's first highly selective HDAC inhibitor used as a single agent in clinical trials for relapsed/refractory lymphoma, has entered pivotal Phase III clinical study, and 5 other indications are in Phase II clinical trials. Up to now, the company has obtained 19 clinical approvals from China's National Medical Products Administration and the US FDA, 34 invention patents including 17 international invention patents, and another 45 international and domestic patents are pending.

By deeply integrating three core technology platforms - "structural biology analysis", "AI-driven drug design", and "organoid-PDX dual-track validation", Zenitar has successfully built a unique "end-to-end" innovative engine for new drug R&D. This engine seamlessly runs through the entire R&D process from target validation, molecular design, molecular optimization to in vivo validation, continuously driving original innovative drugs with novel target mechanisms and differentiated molecular structures to accelerate into clinical development, aiming to address major unmet medical needs worldwide.

The participation of multiple professional investment institutions in this round fully reflects the capital market's recognition of Zenitar's R&D achievements and future potential. Zenitar will continue to adhere to the innovation-driven strategy, accelerate its global layout, further release platform advantages in cutting-edge fields such as structural biology and AI drug design, continuously enhance the adaptability and competitiveness of its products in the international market, and work with global partners to create a multi-win new pattern.

Professor Lijuan Chen, Founder of Zenitar, stated: "In the context of the global pharmaceutical capital market downturn and the slowdown in financing in the biomedical industry, Zenitar's ability to quickly complete the Series B+ capital raising fully demonstrates investors' high recognition of our development strategy and R&D achievements. As the company's 2 core products enter pivotal Phase III clinical studies, we are firmly moving towards international development. 2025 will be the first year of Zenitar's globalization, and we will accelerate the layout of overseas markets, advancing to the central stage of global innovative drugs."

Dr. Kan Chen, Partner of Qiming Venture Partners, said: "Relying on a full-chain innovative drug platform, Zenitar has successfully promoted the efficient clinical transformation of multiple new drugs and demonstrated encouraging clinical efficacy in various therapeutic areas. We believe that with the simultaneous launch of overseas clinical trials, Zenitar will emerge on the global innovative drug stage, showing strong innovative vitality and development potential."

LILY ZHANG, Founding and Managing Partner of TTM Capital, stated: "Zenitar has built multiple global competitive R&D pipelines in the fields of oncology and autoimmune diseases. Its progress in 1 Phase III clinical study and 5 Phase II clinical studies, as well as the achievement of obtaining 19 NMPA and FDA approvals, fully reflect the company's platform strength and R&D capabilities. TTM Capital will leverage its industrial resources and ecosystemic advantages in the healthcare industry to assist Zenitar in accelerating pivotal clinical studies and expanding global layout."

Who we are

TTM Capital is a professional investment institution focused on early-stage investments in the healthcare sector. The founding and managing team been involved in the medical and biotechnology fields for many years, with a background in medical investments from top domestic funds to full industry chain experience from globally leading multinational pharmaceutical companies.
TTM Capital mainly focuses on high-quality investment opportunities in the fields of biopharmaceuticals, medical devices and in vitro diagnostics driven by cutting-edge technology, focusing on segmented tracks with significant advantages, focusing on the global medical market and the "unmet needs" of patients. Persist in empowering and creating synergistic value for invested companies, jointly promote medical innovation, and create value for society.